Pretax income is the income that a company earns before paying income taxes. Evolus's pretax income for the
three
months ended in Dec. 2023 was $-11.7 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-61.5 Mil.
Evolus's pretax margin was -19.22%.
During the past 9 years, Evolus's highest Pretax Margin was -30.44%. The lowest was -300.82%. And the median was -50.01%.
Evolus Pre-Tax Income Historical Data
The historical data trend for Evolus's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Evolus's Pre-Tax Income falls into.
Evolus Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Evolus's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (NAS:EOLS) Pre-Tax Income Explanation
Evolus's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 9 years, Evolus's highest Pretax Margin was -30.44%. The lowest was -300.82%. And the median was -50.01%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Evolus's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EOLS has been successfully added to your 